CG Oncology, Inc.

NasdaqGS:CGON Stock Report

Market Cap: US$2.2b

CG Oncology Management

Management criteria checks 2/4

CG Oncology's CEO is Arthur Kuan, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is $3.93M, comprised of 11.4% salary and 88.6% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $1.17M. The average tenure of the management team and the board of directors is 1.3 years and 6.1 years respectively.

Key information

Arthur Kuan

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage11.4%
CEO tenure7.8yrs
CEO ownership0.05%
Management average tenure1.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

Oct 04
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

CG Oncology: Promising Data, But Looks Expensive

Aug 26

CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jul 25
CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 09

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 06

CEO Compensation Analysis

How has Arthur Kuan's remuneration changed compared to CG Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$72m

Dec 31 2023US$4mUS$449k

-US$68m

Sep 30 2023n/an/a

-US$57m

Dec 31 2022US$1mUS$394k

-US$44m

Compensation vs Market: Arthur's total compensation ($USD3.93M) is about average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: Arthur's compensation has increased whilst the company is unprofitable.

CEO

Arthur Kuan (33 yo)

7.8yrs

Tenure

US$3,933,996

Compensation

Mr. Arthur Kuan serves as Chief Executive Officer and Director at CG Oncology, Inc. since 2017 and also serves as its Chairman since December 2023. Mr. Kuan served as the Chief Operating Officer of CG Onco...

Leadership Team

NamePositionTenureCompensationOwnership
Arthur Kuan
Chairman & CEO7.8yrsUS$3.93m0.053%
$ 1.2m
Ambaw Bellete
President & COO1.3yrsUS$3.03m0%
$ 0
Vijay Kasturi
Chief Medical Officer1.2yrsUS$2.44m0.0019%
$ 42.4k
Corleen Roche
CFO & Secretaryless than a yearno data0.0030%
$ 64.7k
Amy Steele
Vice President of Finance2.8yrsno datano data
Swapnil Bhargava
Chief Technical Officer1.2yrsno datano data
Joshua Patterson
General Counsel & Chief Compliance Officerno datano datano data
Bing Kung
Vice President of Corporate Developmentno datano datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: CGON's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Arthur Kuan
Chairman & CEO7.8yrsUS$3.93m0.053%
$ 1.2m
Leonard Post
Lead Independent Director6.1yrsUS$77.54k0%
$ 0
Victor Tong
Independent Director1.3yrsno datano data
Victoria Sluzky
Member of Chemistryno datano datano data
Richard Peluso
Member of Chemistryno datano datano data
James Mule
Independent Director6.1yrsUS$198.00k0%
$ 0
Susan Graf
Independent Directorless than a yearUS$599.04kno data
Daniel Takefman
Member of Chemistryno datano datano data
Hong Fang Song
Independent Director9yrsno data6.38%
$ 139.6m
Brian Liu
Independent Director2.2yrsno datano data
Richard Rutter
Member of Chemistryno datano datano data

6.1yrs

Average Tenure

57yo

Average Age

Experienced Board: CGON's board of directors are considered experienced (6.1 years average tenure).